Jointown Pharmaceutical Group Co Ltd
Jointown Pharmaceutical Group Co., Ltd engages in pharmaceutical distribution and supply chain business in China and internationally. It is also involved in general agency brand promotion; pharmaceutical industrial self-production and OEM; and pharmaceutical new retail and ten-thousand store alliance plan businesses. In addition, the company provides medical health and technology value-added serv… Read more
Jointown Pharmaceutical Group Co Ltd (600998) - Total Assets
Latest total assets as of September 2025: CN¥112.28 Billion CNY
Based on the latest financial reports, Jointown Pharmaceutical Group Co Ltd (600998) holds total assets worth CN¥112.28 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Jointown Pharmaceutical Group Co Ltd - Total Assets Trend (2007–2024)
This chart illustrates how Jointown Pharmaceutical Group Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Jointown Pharmaceutical Group Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Jointown Pharmaceutical Group Co Ltd's total assets of CN¥112.28 Billion consist of 82.3% current assets and 17.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 17.0% |
| Accounts Receivable | CN¥37.37 Billion | 36.5% |
| Inventory | CN¥22.85 Billion | 22.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥2.20 Billion | 2.2% |
| Goodwill | CN¥799.37 Million | 0.8% |
Asset Composition Trend (2007–2024)
This chart illustrates how Jointown Pharmaceutical Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jointown Pharmaceutical Group Co Ltd's current assets represent 82.3% of total assets in 2024, a decrease from 83.0% in 2007.
- Cash Position: Cash and equivalents constituted 17.0% of total assets in 2024, down from 25.6% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 3.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 36.5% of total assets.
Jointown Pharmaceutical Group Co Ltd Competitors by Total Assets
Key competitors of Jointown Pharmaceutical Group Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
C.Q. Pharmaceutical Holding Co Ltd
SHE:000950
|
China | CN¥67.71 Billion |
|
Shenzhen Glory Medical Co Ltd
SHE:002551
|
China | CN¥3.56 Billion |
|
Shandong Realcan Pharmaceutical Co Ltd
SHE:002589
|
China | CN¥15.33 Billion |
|
Hanmi Science
KO:008930
|
Korea | ₩1.45 Trillion |
|
BCM Alliance Bhd
KLSE:0187
|
Malaysia | RM147.86 Million |
|
Qingdao Baheal Medical INC.
SHE:301015
|
China | CN¥7.59 Billion |
|
Excelsior Medical Co Ltd
TW:4104
|
Taiwan | NT$18.80 Billion |
|
CHC Healthcare Group
TW:4164
|
Taiwan | NT$14.83 Billion |
Jointown Pharmaceutical Group Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Jointown Pharmaceutical Group Co Ltd generates 1.48x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Jointown Pharmaceutical Group Co Ltd generates $ 2.45 in net profit.
Jointown Pharmaceutical Group Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.24 | 1.27 | 1.29 |
| Quick Ratio | 0.93 | 0.98 | 1.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥18.27 Billion | CN¥ 17.45 Billion | CN¥ 14.82 Billion |
Jointown Pharmaceutical Group Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jointown Pharmaceutical Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.00 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 10.4% |
| Total Assets | CN¥102.40 Billion |
| Market Capitalization | $1.61 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Jointown Pharmaceutical Group Co Ltd's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Jointown Pharmaceutical Group Co Ltd's assets grew by 10.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Jointown Pharmaceutical Group Co Ltd (2007–2024)
The table below shows the annual total assets of Jointown Pharmaceutical Group Co Ltd from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥102.40 Billion | +10.35% |
| 2023-12-31 | CN¥92.79 Billion | +0.56% |
| 2022-12-31 | CN¥92.27 Billion | +7.37% |
| 2021-12-31 | CN¥85.94 Billion | +6.32% |
| 2020-12-31 | CN¥80.82 Billion | +13.60% |
| 2019-12-31 | CN¥71.15 Billion | +6.71% |
| 2018-12-31 | CN¥66.67 Billion | +28.10% |
| 2017-12-31 | CN¥52.05 Billion | +34.39% |
| 2016-12-31 | CN¥38.73 Billion | +18.85% |
| 2015-12-31 | CN¥32.58 Billion | +35.07% |
| 2014-12-31 | CN¥24.13 Billion | +29.73% |
| 2013-12-31 | CN¥18.60 Billion | +25.62% |
| 2012-12-31 | CN¥14.80 Billion | +25.05% |
| 2011-12-31 | CN¥11.84 Billion | +45.81% |
| 2010-12-31 | CN¥8.12 Billion | +13.27% |
| 2009-12-31 | CN¥7.17 Billion | +25.33% |
| 2008-12-31 | CN¥5.72 Billion | +29.27% |
| 2007-12-31 | CN¥4.42 Billion | -- |